Premium
Long‐Term Clinical Assessment of Combined ACAC HemoperfusionUltrafiltration in Uremia
Author(s) -
Chang Thomas MingSwi,
Chirito Edward,
Barre Paul,
Cole Craig,
Lister Colin,
Resurreccion Emma
Publication year - 1979
Publication title -
artificial organs
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 76
eISSN - 1525-1594
pISSN - 0160-564X
DOI - 10.1111/j.1525-1594.1979.tb01024.x
Subject(s) - uremia , hemoperfusion , medicine , hematocrit , urea , clinical trial , hemodialysis , chemistry , organic chemistry
ACAC hemoperfusion was used in series with a small fluid removal system for a clinical trial in the treatment of uremia. A 22‐month trial included a pretest control period, test period and a post‐test control period. The most significant observations from this trial are: 1) the predialysis body weight of the patient could be maintained closer to the patient's dry weight; 2) there was a significant increase in hematocrit; and 3) there was insufficient removal of urea. With the development of an effective urea removal system, a more compact artificial kidney than any presently available will become feasible.